- Home
- CZNC vs PRQR Comparison
CZNC vs PRQR Comparison
Compare CZNC & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- PRQR
- Stock Information
- Founded
- CZNC 1864
- PRQR 2012
- Country
- CZNC United States
- PRQR Netherlands
- Employees
- CZNC N/A
- PRQR N/A
- Industry
- CZNC Major Banks
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- PRQR Health Care
- Exchange
- CZNC Nasdaq
- PRQR Nasdaq
- Market Cap
- CZNC 297.0M
- PRQR 179.1M
- IPO Year
- CZNC N/A
- PRQR 2014
- Fundamental
- Price
- CZNC $20.02
- PRQR $2.48
- Analyst Decision
- CZNC
- PRQR Strong Buy
- Analyst Count
- CZNC 0
- PRQR 8
- Target Price
- CZNC N/A
- PRQR $8.88
- AVG Volume (30 Days)
- CZNC 34.7K
- PRQR 352.5K
- Earning Date
- CZNC 08-06-2025
- PRQR 08-07-2025
- Dividend Yield
- CZNC 5.61%
- PRQR N/A
- EPS Growth
- CZNC 15.34
- PRQR N/A
- EPS
- CZNC 1.75
- PRQR N/A
- Revenue
- CZNC $108,114,000.00
- PRQR $21,212,711.00
- Revenue This Year
- CZNC $6.78
- PRQR N/A
- Revenue Next Year
- CZNC $4.59
- PRQR N/A
- P/E Ratio
- CZNC $11.43
- PRQR N/A
- Revenue Growth
- CZNC 5.33
- PRQR 85.91
- 52 Week Low
- CZNC $17.25
- PRQR $1.07
- 52 Week High
- CZNC $22.68
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- CZNC 60.37
- PRQR 74.41
- Support Level
- CZNC $19.81
- PRQR $2.10
- Resistance Level
- CZNC $19.85
- PRQR $2.18
- Average True Range (ATR)
- CZNC 0.39
- PRQR 0.15
- MACD
- CZNC 0.10
- PRQR 0.03
- Stochastic Oscillator
- CZNC 86.06
- PRQR 89.57
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.